Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Equity Average (2016 - 2025)

Viking Therapeutics' Equity Average history spans 11 years, with the latest figure at $676.0 million for Q4 2025.

  • For Q4 2025, Equity Average fell 24.54% year-over-year to $676.0 million; the TTM value through Dec 2025 reached $676.0 million, down 24.54%, while the annual FY2025 figure was $759.7 million, 23.65% up from the prior year.
  • Equity Average for Q4 2025 was $676.0 million at Viking Therapeutics, down from $754.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $927.4 million in Q2 2024 and bottomed at $139.7 million in Q1 2023.
  • The 5-year median for Equity Average is $309.2 million (2023), against an average of $460.1 million.
  • The largest annual shift saw Equity Average decreased 28.53% in 2022 before it surged 358.97% in 2024.
  • A 5-year view of Equity Average shows it stood at $207.5 million in 2021, then dropped by 28.53% to $148.3 million in 2022, then surged by 141.62% to $358.3 million in 2023, then soared by 150.01% to $895.9 million in 2024, then decreased by 24.54% to $676.0 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Equity Average are $676.0 million (Q4 2025), $754.2 million (Q3 2025), and $821.2 million (Q2 2025).